drugset / Trial / NCT04632940
Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids administered every 2 weeks in ambulatory participants with Duchenne muscular dystrophy (DMD) (age 6 to \<12 years).
Timeline
- Start
- 2021-03-03
- Primary completion
- 2023-06-12
- Completion
- 2023-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pamrevlumab | Monoclonal antibody | 35 mg/kg | Intravenous |
| Background | Deflazacort | Other / unclassified | — | Oral |